Christine Fairly Bishop
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christine Fairly Bishop has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alejandra Noreña Puerta
Laboratory for Human Neurophysiology and Genetics, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia
1 shared publication - Brett William Stringer
Institute for Biomedicine and Glycomics, Griffith University, Brisbane, Australia
1 shared publication - Bridget Milky
South Australian Health and Medical Research Institute (SAHMRI), Laboratory for Human Neurophysiology and Genetics, Adelaide, SA, Australia
1 shared publication - Cedric Bardy
Laboratory for Human Neurophysiology and Genetics, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia
1 shared publication - Ganessan Kichenadasse
College of Medicine and Public Health Flinders University Adelaide South Australia Australia
1 shared publication - Lisa M. Ebert
Centre for Cancer biology, Adelaide University, Adelaide, Australia
1 shared publication
Latest Publications
- Open Access
- 27 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (43) , eadf1332
Human cerebrospinal fluid affects chemoradiotherapy sensitivities in tumor cells from patients with glioblastoma
Cancers in the central nervous system resist therapies effective in other cancers, possibly due to the unique biochemistry of the human brain microenvironment composed of cerebrospinal fluid (CSF). However, the impact of CSF on cancer cells and therapeutic efficacy is unknown. Here, we examined the effect of human CSF on glioblastoma (GBM) tumors from 25 patients. We found that CSF induces tumor cell plasticity and resistance to standard GBM treatments (temozolomide and irradiation). We identified nuclear protein 1 (NUPR1), a transcription factor hampering ferroptosis, as a mediator of therapeutic resistance in CSF. NUPR1 inhibition with a repurposed antipsychotic, trifluoperazine, enhanced the killing of GBM cells resistant to chemoradiation in CSF. The same chemo-effective doses of trifluoperazine were safe for human neurons and astrocytes derived from pluripotent stem cells. These findings reveal that chemoradiation efficacy decreases in human CSF and suggest that combining trifluoperazine with standard care may improve the survival of patients with GBM.
- 27 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (43) , eadf1332
Open AccessHuman cerebrospinal fluid affects chemoradiotherapy sensitivities in tumor cells from patients with glioblastoma
Cancers in the central nervous system resist therapies effective in other cancers, possibly due to the unique biochemistry of the human brain microenvironment composed of cerebrospinal fluid (CSF). However, the impact of CSF on cancer cells and therapeutic efficacy is unknown. Here, we examined the effect of human CSF on glioblastoma (GBM) tumors from 25 patients. We found that CSF induces tumor cell plasticity and resistance to standard GBM treatments (temozolomide and irradiation). We identified nuclear protein 1 (NUPR1), a transcription factor hampering ferroptosis, as a mediator of therapeutic resistance in CSF. NUPR1 inhibition with a repurposed antipsychotic, trifluoperazine, enhanced the killing of GBM cells resistant to chemoradiation in CSF. The same chemo-effective doses of trifluoperazine were safe for human neurons and astrocytes derived from pluripotent stem cells. These findings reveal that chemoradiation efficacy decreases in human CSF and suggest that combining trifluoperazine with standard care may improve the survival of patients with GBM.